GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Molecular Partners AG
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics (DARPins). Its stock price represents a venture capital bet on the success of its scientific platform. The chart reflects high volatility associated with news about clinical trials and partnerships.
Share prices of companies in the market segment - Oncology platforms
Molecular Partners AG is a Swiss biotech company developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. We classify it as an "Oncology Platform" due to its unique technology. The chart below illustrates the dynamics of this innovative and highly competitive sector.
Broad Market Index - GURU.Markets
Molecular Partners is a Swiss biotech company developing a new class of protein drugs, DARPin, for the treatment of cancer and viral diseases. Its shares (ADR) are part of the GURU.Markets index. The chart below shows how its performance compares to the overall US market.
Change in the price of a company, segment, and market as a whole per day
MOLN - Daily change in the company's share price Molecular Partners AG
The change_co indicator for Molecular Partners, an oncology company, measures its high volatility. It reflects its sensitivity to news about clinical trials. This indicator is a key component in the formulas on System.GURU.Markets for analyzing the biotech sector.
Daily change in the price of a set of shares in a market segment - Oncology platforms
Molecular Partners AG is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with MOLN's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Molecular Partners is a biotech company focused on cancer treatment. Its success depends on scientific breakthroughs, so its shares are subject to significant fluctuations based on research news. These unique movements contribute to the overall market volatility picture shown below.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Molecular Partners AG
Molecular Partners AG's year-to-date performance is a story about its unique DARPin protein drug development platform. Its market capitalization growth over the past 12 months is driven by progress in its oncology programs and partnerships with major pharmaceutical companies. Clinical success will be a fundamental validation of the advantages of its technology.
Annual dynamics of market capitalization of the market segment - Oncology platforms
Molecular Partners AG is a Swiss biotechnology company developing a new class of protein therapeutics (DARPins). Its innovative platform is its key advantage. Its stock price reflects the high potential of its technology and the risks associated with clinical trials.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Molecular Partners is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor expectations for the success of its innovative platform trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Molecular Partners AG
Molecular Partners develops protein therapeutics (DARPins). Its monthly performance is determined by developments in the biotech pipeline. News of partnerships with major pharmaceutical companies, as well as data from clinical trials, are the main catalysts that can cause dramatic changes in the company's valuation.
Monthly dynamics of market capitalization of the market segment - Oncology platforms
Molecular Partners is developing a new class of protein drugs called DARPins for the treatment of oncological and viral diseases. This is an innovative therapeutic platform. The chart below shows the overall dynamics in the oncology platform sector, where investors are evaluating the potential of breakthrough technologies for the development of new drugs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Shares of biotech companies with unique scientific platforms often move on their own news about partnerships and research. The chart below shows general market trends. Is Molecular Partners living its own life, or does its status as a European company add momentum?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Molecular Partners AG
The weekly performance of Molecular Partners, a Swiss biotech company, reflects the potential of their unique protein platform, DARPin. Share prices are responding to news of partnerships with major pharma and clinical data that may confirm the effectiveness of their approach in oncology and virology.
Weekly dynamics of market capitalization of the market segment - Oncology platforms
Molecular Partners uses the innovative DARPin protein platform to develop oncology drugs. Success in this biotech segment depends on breakthroughs in research. This chart allows us to separate the company's progress from the overall market: are stock fluctuations driven by news about the DARPin platform or by general trends in oncology?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Molecular Partners is a Swiss biotech company. Its shares may be less dependent on general economic cycles, but they are very sensitive to regulatory announcements and trial data. This chart will help you understand whether Molecular Partners shares are in a world of their own, or whether the overall market environment still influences their price.
Market capitalization of the company, segment and market as a whole
MOLN - Market capitalization of the company Molecular Partners AG
The Molecular Partners market capitalization chart tells the story of a Swiss biotech company with a unique platform for creating protein-based drugs (DARPins). Its dynamics reflect both successes in developing, for example, an antiviral drug, and setbacks. The trajectory reflects the market's assessment of the potential of its scientific platform for creating a whole new range of drugs.
MOLN - Share of the company's market capitalization Molecular Partners AG within the market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics called DARPin. Its market share reflects the potential of its unique scientific platform for drug discovery. The chart below shows how the market views its innovative approach compared to traditional antibodies.
Market capitalization of the market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics (DARPins). The chart below shows the overall market capitalization of the oncology sector. Its dynamics provide the backdrop against which the company is trying to demonstrate the advantages of its unique scientific platform.
Market capitalization of all companies included in a broad market index - GURU.Markets
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics (DARPins). Its market capitalization reflects its unique scientific platform. Its performance on the overall chart reflects how the market perceives the potential of new approaches to drug development that could outperform traditional antibodies.
Book value capitalization of the company, segment and market as a whole
MOLN - Book value capitalization of the company Molecular Partners AG
Molecular Partners' book value is derived from its equity and patents for the unique DARPin platform for creating a new class of protein drugs. This provides a tangible, scientific foundation for the development of targeted therapies in oncology and virology. How has this Swiss biotech asset changed? The chart below shows its dynamics.
MOLN - Share of the company's book capitalization Molecular Partners AG within the market segment - Oncology platforms
Molecular Partners is developing a new class of protein therapeutics (DARPins), which requires advanced laboratories and manufacturing facilities. The chart shows the share of these unique tangible assets in the biotech sector, reflecting the physical foundation of its platform.
Market segment balance sheet capitalization - Oncology platforms
Molecular Partners is a biotech company developing a new class of protein therapeutics. Its model is focused on R&D. A book value chart will show how modest its physical assets are, while its scientific platform offers enormous potential.
Book value of all companies included in the broad market index - GURU.Markets
Molecular Partners AG is developing a new class of protein drugs, DARPin. Its book value is derived from its unique technology platform, laboratories, and manufacturing facilities. The chart shows the material value of this biotech company, whose assets are a factory for the production of high-precision therapeutic molecules.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Molecular Partners AG
Molecular Partners owns laboratories, but its value lies in its unique DARPin platform. The chart shows the premium the market pays for the technology itself, which creates next-generation drugs. This is a valuation of the intellectual property and potential of the entire platform, not individual assets.
Market to book capitalization ratio in a market segment - Oncology platforms
Molecular Partners is developing a new class of protein therapeutics called DARPins. Its value lies in this unique scientific platform. The chart shows how highly investors value the potential of this technology for new drug development compared to its current assets.
Market to book capitalization ratio for the market as a whole
Molecular Partners AG is developing a new class of protein drugs called DARPins, which may be more effective than traditional antibodies. The company's value lies in its unique scientific platform. This chart shows the overall valuation, but how does the market value a biotech company that has built its own "factory" for producing innovative protein drugs?
Debts of the company, segment and market as a whole
MOLN - Company debts Molecular Partners AG
Molecular Partners, a Swiss biotech company, uses its unique technology platform to create innovative drugs. This chart shows how it funds the lengthy and expensive research and development process for its entire pipeline of candidates, turning science into potential therapeutics.
Market segment debts - Oncology platforms
Molecular Partners is developing a new class of protein therapeutics (DARPins) for oncology and virology. This unique platform requires significant investment in research to prove its effectiveness. This chart shows how the company funds its innovative developments compared to other biotech platforms.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Molecular Partners AG
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics. This chart shows how much it relies on debt to finance its unique scientific platform. For investors, this is a way to assess the financial risk involved in developing breakthrough drugs that could change the standard of care.
Market segment debt to market segment book capitalization - Oncology platforms
Molecular Partners AG is developing a new class of protein therapeutics, DARPins, for the treatment of cancer and viral diseases. This chart shows the overall debt burden in the biotech platform sector. It helps understand how the industry funds its innovative research and how Molecular Partners' partnership business model impacts its financial structure.
Debt to book value of all companies in the market
Molecular Partners develops next-generation protein therapeutics. Like most biotech companies in the R&D stage, it avoids debt, relying on investor capital. This chart, showing the overall market leverage, vividly illustrates the gap between innovative but unprofitable companies and mature businesses that rely on debt.
P/E of the company, segment and market as a whole
P/E - Molecular Partners AG
This metric for Molecular Partners, a Swiss biopharmaceutical company, represents the valuation of its unique DARPin technology platform. The multiple reflects investors' belief in the potential of this technology to create a new class of drugs, as well as the value of its partnerships with major pharmaceutical companies.
P/E of the market segment - Oncology platforms
Molecular Partners' protein drug development is an innovation platform. This chart shows the average valuation for biopharmaceutical companies. It helps us understand that Molecular Partners is valued as a scientific platform capable of developing multiple drugs, and its value depends on the success of its partnerships with major pharma.
P/E of the market as a whole
Molecular Partners AG is developing a new class of protein therapeutics called DARPins for use in oncology and virology. This unique scientific platform offers a unique perspective. This biotech sentiment chart helps understand how the market views the potential of this technology compared to more traditional approaches, such as monoclonal antibodies, against the backdrop of overall market sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Molecular Partners AG
Molecular Partners is a Swiss biotech company developing DARPin protein therapies for the treatment of cancer and viral diseases. This chart illustrates investor expectations for its unique technology platform. The trend reflects the potential for clinical development and partnerships with major pharmaceutical companies.
%20P%2FE%20Molecular%20Partners%20AG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Molecular-Partners-AG&v=1772598021828 "Chart of the company's future (projected) P/E Molecular Partners AG")
Future (projected) P/E of the market segment - Oncology platforms
Molecular Partners AG is developing a new class of protein therapeutics called DARPins for the treatment of cancer and viral diseases. This chart shows profitability expectations for the oncology sector. It allows us to assess how investors view the uniqueness and potential of this technological platform compared to traditional antibodies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-platforms&v=1772598021866 "Future (projected) P/E graph of the market segment - Oncology platforms")
Future (projected) P/E of the market as a whole
Molecular Partners AG is a Swiss biotech company developing a new class of protein drugs called DARPin for the treatment of cancer and viral diseases. This chart reflects sentiment in the healthcare sector. For a company with a unique scientific platform, it shows how willing investors are to invest in innovative technologies with long-term potential.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772598021940 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Molecular Partners AG
Molecular Partners AG is developing a new class of protein therapeutics called DARPins for the treatment of cancer and viral diseases. The financial results shown here are a combination of research expenses and revenue from collaborations with major pharmaceutical companies. The graph reflects progress in validating this unique therapeutic platform.
Profit of companies in the market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing a new class of protein drugs called DARPin. These molecules can be used to treat cancer and viral diseases. This chart illustrates how innovative scientific platforms like DARPin can generate an entire drug pipeline and shape future profitability in the pharmaceutical industry.
Overall market profit
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics (DARPin). Its success depends on clinical trial results and partnerships with major pharmaceutical companies. For such innovators, a strong economic environment, as reflected in this chart, means better access to financing and a more active M&A market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Molecular Partners AG
Molecular Partners is a Swiss biotech company developing DARPin protein drugs for the treatment of cancer and viral diseases. The revenue forecast in this chart reflects analysts' expectations for the success of its clinical programs and potential partnerships with major pharmaceutical companies.
%20profit%20of%20the%20company%20Molecular%20Partners%20AG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Molecular-Partners-AG&v=1772598022081 "Graph of future (projected) profit of the company Molecular Partners AG")
Future (predicted) profit of companies in the market segment - Oncology platforms
Molecular Partners is developing a new class of protein therapeutics called DARPin for the treatment of cancer and viral diseases. This technology promises high specificity and versatility. This chart shows the revenue forecast for the oncology platforms, providing context for assessing the potential of the innovative DARPin platform within the broader biotech industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-platforms&v=1772598022101 "Graph of future (predicted) profits of companies in a market segment - Oncology platforms")
Future (predicted) profit of the market as a whole
Molecular Partners is a Swiss biotech company developing protein therapeutics (DARPins). Its success depends on progress in research. The overall market situation, reflected in this chart, influences the willingness of large pharmaceutical companies to enter into partnerships and the availability of funding for clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772598022163 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Molecular Partners AG
Molecular Partners is developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. This chart shows how investors value the partnership revenue and the potential of its unique technology platform. This valuation is a bet on the clinical and commercial success of this innovative technology.
P/S market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing a new class of protein drugs called DARPin. This chart shows the industry average market capitalization to revenue ratio, which provides insight into the market's perceived potential for this unique technology platform to develop treatments for cancer and viral diseases.
P/S of the market as a whole
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics called DARPin. Its platform enables the creation of drugs for the treatment of cancer and viral diseases. This overall market valuation chart helps understand how investors value unique biotech technology platforms that can generate multiple products.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Molecular Partners AG
Molecular Partners is developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. This chart shows how the market values the company relative to its future sales. It reflects investor expectations for the success of its unique technology platform and clinical development.
%20P%2FS%20Molecular%20Partners%20AG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Molecular-Partners-AG&v=1772598022344 "The graph of the company's future (projected) P/S Molecular Partners AG")
Future (projected) P/S of the market segment - Oncology platforms
Molecular Partners is developing a new class of protein drugs called DARPin for the treatment of cancer and viral diseases. This technology promises high specificity and versatility. This chart shows how the market views the scientific potential of its platform and future revenue compared to other oncology biotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-platforms&v=1772598022424 "Future (projected) P/S market segment graph - Oncology platforms")
Future (projected) P/S of the market as a whole
Molecular Partners is a Swiss biotech company developing the DARPin protein drug. Its valuation is based on the potential of its scientific platform and partnerships. This graph of general expectations for MOLN is a baseline. The company's success depends on clinical data, not the overall economic climate, and could create its own powerful upward trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772598022462 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Molecular Partners AG
This chart shows the financial model of a biotech company. For Molecular Partners, it reflects revenues from upfront and milestone payments from major pharmaceutical partners for the joint development of innovative protein therapeutics (DARPins) for the treatment of cancer and viral infections.
Sales of companies in the market segment - Oncology platforms
Molecular Partners AG is developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. This innovative platform has the potential to transform therapeutic approaches. This chart shows revenues for oncology platforms, and the future commercialization of DARPin technology could become a key growth driver for the entire industry.
Overall market sales
Molecular Partners is a Swiss biotechnology company developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. Its innovative platform exemplifies how fundamental science is being transformed into potential treatments, advancing the entire healthcare industry, one of the pillars of the modern economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Molecular Partners AG
Molecular Partners is developing a new class of protein therapeutics, called DARPin, for the treatment of cancer and viral diseases. The company's future sales are dependent on the success of its clinical programs and partnerships. This timeline reflects the expected commercialization of this unique therapeutic platform.
%20sales%20of%20the%20company%20Molecular%20Partners%20AG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Molecular-Partners-AG&v=1772598022617 "Schedule of future (projected) sales of the company Molecular Partners AG")
Future (projected) sales of companies in the market segment - Oncology platforms
Molecular Partners AG is developing a new class of protein therapeutics called DARPin. The oncology platform sector forecast highlights expectations for innovative technologies. It helps assess how the company's unique approach to creating multi-target drugs can find its niche amidst overall trends in anti-cancer drug development.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-platforms&v=1772598022619 "Schedule of future (projected) sales of companies in the market segment - Oncology platforms")
Future (projected) sales of the market as a whole
Molecular Partners is a Swiss biotech company developing DARPin protein therapies for the treatment of cancer and viral diseases. Its prospects are determined by the success of clinical trials. The overall economic situation, reflected in this chart, does not affect the need for treatment but is important for assessing the investment attractiveness of the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772598022644 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Molecular Partners AG
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics called DARPin. Its financial model is based on partnerships with major pharmaceutical companies and its own research. This chart illustrates the complex balance between revenue from partnerships and the high costs of developing its unique platform.
Market segment marginality - Oncology platforms
Molecular Partners AG is developing a new class of protein therapeutics called DARPins for use in oncology and virology. Profitability depends on the success of its platform and partnerships with major pharmaceutical companies. This chart shows the company's operational structure and R&D investment efficiency compared to other biotech platforms.
Market marginality as a whole
Molecular Partners AG is a Swiss biotech company developing a new class of protein therapeutics known as DARPin. This chart shows the company's overall profit margin. In contrast, Molecular Partners demonstrates a platform-based model. Its profitability depends on the success of clinical trials and partnerships with major pharmaceutical companies.
Employees in the company, segment and market as a whole
Number of employees in the company Molecular Partners AG
Molecular Partners is a Swiss biotech company developing DARPin protein drugs. Its staff consists primarily of research scientists. The dynamics in this graph reflect its scientific activity: growth is driven by the expansion of R&D programs and partnerships with major pharmaceutical companies for joint development.
Share of the company's employees Molecular Partners AG within the market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. This chart illustrates its unique scientific platform, reflecting the proportion of biochemists and protein engineers working on this cutting-edge technology within the company.
Number of employees in the market segment - Oncology platforms
Molecular Partners AG is developing a new class of protein therapeutics called DARPin. This chart shows the dynamics of this innovative biotech segment. The growth of the research team here signifies progress in the creation of highly targeted drugs that could offer new solutions for the treatment of cancer and viral diseases.
Number of employees in the market as a whole
Molecular Partners AG develops protein-based therapies for the treatment of cancer and viral diseases. Like many biotech companies, their overall workforce is not a determining factor. Expanding their research and development staff is driven by progress in drug development and partnerships with major pharmaceutical companies, not by economic conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Molecular Partners AG (MOLN)
Molecular Partners is a Swiss biotech company developing a new class of protein drugs, DARPin. It offers a unique scientific platform. This chart clearly demonstrates how intellectual capital is valued. The high capitalization per employee indicates that the market sees enormous value in the technology itself, which can generate numerous drug candidates.
%20of%20the%20company%20Molecular%20Partners%20AG%20(MOLN)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Molecular-Partners-AG-MOLN&v=1772598022893 "Chart of market capitalization per employee (in thousands of dollars) of the company Molecular Partners AG (MOLN)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology platforms
Molecular Partners is developing a new class of protein therapeutics. It's a science-intensive business where breakthroughs are achieved by small teams of researchers. This chart shows the high concentration of intellectual capital: the company's market value per employee reflects investors' faith in the uniqueness and potential of its scientific platform.
%20by%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-platforms&v=1772598022919 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology platforms")
Market capitalization per employee (in thousands of dollars) for the overall market
Molecular Partners is a Swiss biotech company developing a new class of protein drugs called DARPin. This chart shows a high valuation per employee, which is typical for companies with a unique scientific platform that can generate numerous potential drugs, leading to a high company valuation.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772598022925 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Molecular Partners AG (MOLN)
Molecular Partners is a Swiss biotech company developing a new class of proteins (DARPin) for the treatment of cancer and viral diseases. It's an R&D platform. This chart shows how productive their science is. It measures how much profit (from partnerships, like with Novartis) or loss (from R&D) each of their highly skilled scientists creating these innovative molecules generates.
%20Chart%20Molecular%20Partners%20AG%20(MOLN)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Molecular-Partners-AG-MOLN&v=1772598022936 "Company Profit Per Employee (in thousands of dollars) Chart Molecular Partners AG (MOLN)")
Profit per employee (in thousands of dollars) in the market segment - Oncology platforms
Molecular Partners is using its DARPin platform to develop new classes of protein drugs. For this clinical-stage biotech, the presented schedule serves as a benchmark for the future. The company is currently investing in R&D. Its effectiveness is measured by the speed and success of developments, which should lead to licensing deals or sales, with profitability per employee exceeding the benchmark.
%20in%20the%20market%20segment%20-%20Oncology%20platforms&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-platforms&v=1772598022950 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology platforms")
Profit per employee (in thousands of dollars) for the market as a whole
Molecular Partners uses DARPin technology to create a new class of protein drugs. It's a biotech platform that can generate numerous potential drugs. The company's profitability depends on the success of partnerships (for example, with Novartis) and licensing fees, which cover the costs of its in-house research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772598022989 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Molecular Partners AG (MOLN)
Molecular Partners is developing a new class of protein therapeutics (DARPins). This chart demonstrates the effectiveness of its model, which relies on partnerships with major pharmaceutical companies. Revenue from licensing fees and milestones allows the company to generate revenue with a small staff, reflecting this high productivity metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Molecular-Partners-AG-MOLN&v=1772598023014 "Sales chart per company employee Molecular Partners AG (MOLN)")
Sales per employee in the market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing protein therapeutics (DARPin technology). It is a platform for creating drugs against cancer and viruses. This metric reflects how productively their research team generates revenue, primarily through major partnerships with pharmaceutical giants, a key metric for a platform company.
Sales per employee for the market as a whole
Molecular Partners is a Swiss biotech company using its proprietary DARPin platform to develop new drugs. Their business model is R&D and partnerships. This chart shows revenue per employee. This revenue typically comes from upfront and milestone payments from large pharmaceutical partners (like Amgen). It reflects the value of their scientific platform, not sales.
Short shares by company, segment and market as a whole
Shares shorted by company Molecular Partners AG (MOLN)
Molecular Partners is a Swiss biotech company developing protein therapeutics (DARPin technology). This chart shows bearish bets. Bears may be concerned that the company's developments (including those in oncology) will not compete with established treatments, such as monoclonal antibodies, or will fail in late-stage trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Molecular-Partners-AG-MOLN&v=1772598023061 "Short Shares Chart for the Company Molecular Partners AG (MOLN)")
Shares shorted by market segment - Oncology platforms
Molecular Partners AG develops protein drugs (DARPin technology) for the treatment of cancer and viral diseases. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (FDA) across the sector.
Shares shorted by the overall market
Molecular Partners is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing that MOLN will be unable to raise funds for R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Molecular Partners AG (MOLN)
Molecular Partners is a biotech company developing protein therapeutics (DARPins). The stock is volatile and dependent on R&D and partnerships. This chart reading above 70 may reflect positive trial data or new deals. Oversold levels (<30) are often associated with research setbacks or funding concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Molecular-Partners-AG-MOLN&v=1772598023106 "RSI 14 indicator chart for the company's stock Molecular Partners AG (MOLN)")
RSI 14 Market Segment - Oncology platforms
Molecular Partners (MOLN) — "nano-antibodies." This Swiss biotech creates *DARPins* — "micro-proteins" (smaller than antibodies) that "attack" cancer and viruses. The RSI_14_Seg for "Oncology" (biotech) reflects the overall sentiment. It helps us understand: is MOLN's volatility just their "DARPins platform" or is the *entire* sector "overheated?"
RSI 14 for the overall market
Molecular Partners (MOLN) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MOLN (Molecular Partners AG)
Molecular Partners is a Swiss biotech company that developed the DARPin platform, a new class of protein-based drugs for the treatment of oncology and viral diseases. This chart shows the analysts' average 12-month forecast, reflecting their assessment of the platform's potential and the success of its partnership programs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MOLN-Molecular-Partners-AG&v=1772598023147 "A chart showing analyst consensus forecasts for the expected stock price. MOLN (Molecular Partners AG)")
The difference between the consensus estimate and the actual stock price MOLN (Molecular Partners AG)
Molecular Partners (MOLN) is a Swiss biotech company developing DARPins, a new class of protein-based oncology drugs. This chart shows the valuation of their platform. It measures the gap between the price and the consensus target, reflecting the high, yet speculative, potential analysts see in their unique R&D technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MOLN-Molecular-Partners-AG&v=1772598023161 "A chart showing the difference between the consensus forecast and the actual stock price. MOLN (Molecular Partners AG)")
Analyst consensus forecast for stock prices by market segment - Oncology platforms
Molecular Partners is a Swiss biotech company developing "DARPins," a new class of protein drugs (an alternative to antibodies) for oncology and virology. This chart shows analysts' overall expectations for the oncology platform sector. It reflects whether experts believe in "next-generation" R&D platforms.
Analysts' consensus forecast for the overall market share price
Molecular Partners is a Swiss biotech company developing a new class of protein drugs (DARPins) for the treatment of cancer and viral diseases. This chart shows the overall risk appetite. For Molecular Partners, an innovative platform company, overall market optimism is important for funding research and partnering with Big Pharma.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Molecular Partners AG
Molecular Partners is a Swiss biotech company with a unique facility: they are developing DARPin, a new class of synthetic protein therapeutics that are smaller and simpler than antibodies. This chart is an assessment of their R&D platform. It reflects their progress in oncology and virology, as well as their ability to partner with major pharma companies to license their technology.
AKIMA Market Segment Index - Oncology platforms
Molecular Partners is a Swiss biotech company developing a new class of protein therapeutics (DARPins) for the treatment of cancer and viral diseases. This chart shows the average index for the oncology sector. It allows investors to assess how the innovative DARPins platform compares to the industry average based on aggregate metrics.
The AKIM Index for the overall market
Molecular Partners is a Swiss biotech company, a pioneer in the DARPin class of drugs (an alternative to antibodies) for oncology and virology. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this innovative platform with its unique technology compares to overall economic trends.
